Loading
A phase 2 trial of Disitamab vedotin, Zimberelimab in cervical cancer, run by RemeGen Co., Ltd., now recruiting.
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer is a phase 2 interventional study registered as NCT06155396 by RemeGen Co., Ltd., with 116 participants planned, started 2024-01-11 and due to reach its primary completion in 2027-06-30. Interventions recorded: Disitamab Vedotin, Zimberelimab. Conditions listed: Cervical Cancer. No results are recorded here; the registry entry is the source.
Shares Zimberelimab, Recurrent or metastatic cervical cancer, Cervical cancer, Immune checkpoint inhibitors.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC).
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC), Immune checkpoint inhibitors.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC), Immune checkpoint inhibitors.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC), Immune checkpoint inhibitors.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC), Immune checkpoint inhibitors.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC), Immune checkpoint inhibitors.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC).